Overview

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Status:
Not yet recruiting
Trial end date:
2026-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.
Collaborator:
Biohaven Pharmaceutical Holding Company Ltd.